BioClinica Names CEO

John Hubbard, Ph.D., FCP, has been appointed chief executive officer and a member of the board of directors at BioClinica, Inc., effective January 5, 2015. Dr. Hubbard joins the company from Pfizer, where he has served as senior vice president and worldwide head of development operations. Dr. Hubbard succeeds Mark Weinstein.
 
Dr. Hubbard has 30 years of pharmaceutical experience and spearheaded R&D initiatives for some of the industry’s premier organizations. At Pfizer, he was responsible for more than 450 Phase I-IV clinical projects per year. He also served on the taskforce that redesigned Pfizer’s R&D organization. Prior to Pfizer, Dr. Hubbard was group president of ICON plc’s clinical research services business, and also held management positions at PAREXEL, Revlon Health Care Group and Hoechst Marion Roussel Pharmaceuticals (now owned by Sanofi).
 
“John is ideally suited to lead BioClinica.  His breadth of experience in virtually every aspect of the drug development process gives him a unique understanding of our customers’ needs, and how BioClinica can support them in efficiently managing the complexities of their trials,” said Jeffrey McMullen, chairman, BioClinica.
 
He added, “On behalf of the board, I’d like to thank Mark for his years of service to BioClinica.  He has done an outstanding job of bringing together BioClinica and CCBR-SYNARC’s capabilities following their merger earlier this year. The company is strongly positioned to offer customers a comprehensive suite of clinical trial solutions, including imaging services, patient recruitment, cardiac safety and eClinical services.”